BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Forest Laboratories, Inc. 

909 Third Avenue

New York  New York  10022-4731  U.S.A.
Phone: 212-421-7850 Fax: 212-750-9152


View Clinical Trials from BioPharm Insight

Explore your potential. Discover the rewards.

At Forest Laboratories, we believe in the power of potential. As one of the fastest growing pharmaceutical companies, we are committed to developing a talented, diverse workforce where individuals can learn, achieve and grow.

Highly skilled scientific teams within our Forest Research Institute enable us to license compounds at virtually any stage—from preclinical development to products that are ready for FDA review—and then complete the development and regulatory work to successfully bring these new products to market. Our products, including Lexapro®, Namenda® and Benicar®, help treat a range of conditions such as depression, anxiety, Alzheimer’s disease and hypertension.

In addition to further developing our established therapeutic franchises (central nervous system, cardiovascular and respiratory), we are expanding the scope of our pipeline to address a wider range of health concerns that affect people every day, such as inflammation and pain. This growth is creating significant new career opportunities, and we invite energetic, skilled professionals to join Forest and contribute to our future success.

Employees are the engine of our rapid growth, and in return we offer the incentives and benefits for a healthy work/life balance.

For career opportunities on Long Island, New Jersey and NYC please visit:

Last Updated: 06-01-2006

 Key Statistics

Ownership: Public

Web Site: Forest Laboratories, Inc.
Employees: 4,300
Symbol: FRX



Recordati S.p.A  Licensing agreement for the development of lercanidipine, a long-acting dihydropyridine calcium channel blocker for the treatment of hypertension.

Sankyo Pharma Inc.  Developer and Forest's partner in the promotion of Benicar, an angiotensin II receptor blocker (ARB) for the treatment of hypertension.

H. Lundbeck A/S  Forest's partner for many of the drug compounds that we develop, manufacture and market in the U.S. for central nervous system disorders, including Lexapro.

Merz Pharma GmbH & Co. KGaA  Licensing agreement for the development and marketing in the U.S. of memantine for the treatment of Alzheimer's Disease and neuropathic pain. Licensing agreement for neramexane, a patented novel NMDA receptor antagonist that is being investigated for a broad range of possible indications related central nervous system disorders.

Rotta Research Laboratorium S.p.A.  Licensing agreement for the development and marketing in the U.S. of dexloxiglumide for the treatment of patients with constipation-prone irritable bowel syndrome (IBS).

 Company News
Actavis (ACT) Takes Axe To Forest Laboratories, Inc. (FRX) Again; Cuts 100 Jobs In New York 10/23/2014 6:04:23 AM
Forest Laboratories, Inc. (FRX) Lays Off 200; Regional Sales Office Will Remain 7/9/2014 10:58:31 AM
Actavis (ACT) Announces Final Stockholder Merger Consideration Election Results In Connection With Forest Laboratories, Inc. (FRX) Acquisition 7/2/2014 8:33:26 AM
Actavis plc Appoints New Members And Announces Changes To Board Of Directors Following Close Of Forest Laboratories, Inc. (FRX) Acquisition 7/1/2014 11:52:27 AM
Actavis (ACT) Completes Forest Laboratories, Inc. (FRX) Acquisition 7/1/2014 10:31:10 AM
Actavis (ACT) And Forest Laboratories, Inc. (FRX) Receive U.S. FTC Clearance For Actavis' Proposed Acquisition Of Forest 7/1/2014 10:15:29 AM
Actavis (ACT) And Forest Laboratories, Inc. (FRX) Announce Preliminary Stockholder Merger Consideration Election Results 6/30/2014 8:57:10 AM
Actavis (ACT) And Forest Laboratories, Inc. (FRX) Announce Tentative Election Deadline Of June 27, 2014 6/24/2014 10:20:44 AM
Forest Laboratories, Inc. (FRX) To Present Cariprazine Data At The International College Of Neuropsychopharmacology World Congress 6/23/2014 12:21:18 PM
Actavis (ACT) And Forest Laboratories, Inc. (FRX) Announce Appointment Of C. David Nicholson, Phd To Lead Actavis Global Brands Research And Development 6/23/2014 8:13:36 AM